close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

137.31 -10.06 (-6.83%)
Streaming Delayed Price Updated: 9:47 AM EDT, Oct 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Why the quality investor may take a look at NASDAQ:NBIX.
A fundamental analysis of (NASDAQ:NBIX): Analyzing the Quality Characteristics of NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Earnings Summary: Neurocrine Biosciences Q4
 
Via Benzinga
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza. 
Via Investor's Business Daily
Earnings Scheduled For February 6, 2025
 
Via Benzinga
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
 
Via Benzinga
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) qualifies as a high growth stock and is consolidating. 
Via Chartmill
NASDAQ:NBIX: good value for what you're paying.
Investors should take notice ofNEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
What Analysts Are Saying About Neurocrine Biosciences Stock
 
Via Benzinga
NASDAQ:NBIX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NEUROCRINE BIOSCIENCES INC may be an undervalued stock option. NASDAQ:NBIX retains a strong financial foundation and an attractive price tag. 
Via Chartmill
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal. 
Via Benzinga
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX). 
Via Chartmill
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Deserves Consideration as a Quality Investment.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Exhibits Quality Stock Traits. Here's Why. 
Via Chartmill
Neurocrine Biosciences Stock Sees RS Rating Upgrade
Neurocrine Biosciences stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 67 to 71. 
Via Investor's Business Daily
While growth is established for NASDAQ:NBIX, the stock's valuation remains reasonable.
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:NBIX qualifies as a high growth stock and is consolidating.
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Looking for growth without the hefty price tag? Consider NASDAQ:NBIX. 
Via Chartmill
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
Via Benzinga
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Neurocrine's Crenessity receives FDA approval as a groundbreaking adjunctive treatment for classic CAH, offering a novel approach to hormone regulation. 
Via Benzinga
Neurocrine Wins FDA Approval For Genetic Disorder Drug
The company can launch within a week, says Chief Executive Kyle Gano. 
Via Investor's Business Daily
Screening For Black Friday Bargains In The Stock Market
 
Via Benzinga
For those who appreciate growth without the sticker shock, NASDAQ:NBIX is worth considering.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a growth opportunity that won't break the bank. 
Via Chartmill
NASDAQ:NBIX stands out as a stock that provides good value for the fundamentals it showcases.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals. 
Via Chartmill
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio
AbbVie stock drops after emraclidine fails Phase 2 trials for schizophrenia, raising questions about its neuroscience strategy and boosting competition for Cobenfy. 
Via Benzinga
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences
 
Via Benzinga
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today